Roth MKM Maintains Neutral on Orthofix Medical, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jason Wittes has maintained a Neutral rating on Orthofix Medical (NASDAQ:OFIX) and increased the price target from $12 to $15.
March 07, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Orthofix Medical's price target has been raised from $12 to $15 by Roth MKM, while maintaining a Neutral rating.
The increase in price target by a reputable analyst could lead to positive investor sentiment towards OFIX, potentially driving up its stock price in the short term. However, the Neutral rating suggests that the analyst sees limited upside beyond the new target, tempering expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100